CTOs on the Move

Eikon Therapeutics

www.eikontx.com

 
Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the interface of biology, engineering and chemistry to discover novel treatments for life-threatening diseases. Eikon`s discovery platform is built on groundbreaking innovations from its founders (Nobel Prize, 2014), culminating in the creation of microscopes which enable real time, molecular-resolution measurements of protein movement in living cells.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.eikontx.com
  • 3929 Point Eden Way
    Hayward, CA USA 94545
  • Phone: 341.777.0566

Executives

Name Title Contact Details
John Shin
Senior Director, Information Technology & Cloud Profile
Russ Berman
Chief Technology Officer Profile
Ashish Kheterpal
Chief Information Officer Profile
John Shin
Director Information Technology Infrastructure Profile

Similar Companies

MBL

MBL is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CK Life Sciences Int'l. Inc

CK Life Sciences Int'l. Inc is a Kirkland, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mixture Sciences Inc

Mixture Sciences Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MedWorxs

MedWorxs is a Evergreen, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aravive

Aravive, Inc., is a clinical stage biotechnology company focused on developing new therapies that target important survival pathways for both solid tumors as well as hematologic malignancies. Our primary therapeutic focus is the GAS6-AXL pathway, where AXL receptor signaling plays a critical role in multiple types of malignancies by promoting metastasis and cancer cell survival. Our technology, originated in the laboratories of Drs. Amato Giaccia and his colleagues at Stanford University, uses genetic screening to identify critical targets for the development of therapeutic molecules for cancer therapy while sparing healthy cells. This strategy is designed to enable us to interrupt oncogenic signals and, using our high-affinity decoy receptors, outcompete cancer`s ability to grow, metastasize and acquire resistance to treatments. We believe our unique cancer therapies may hold promise as a monotherapy or in combination with other cancer treatments, augmenting the anti-tumor activity of radiotherapy, chemotherapy, immuno-therapeutics and cancer vaccines. By targeting advanced or metastatic disease, our approach has the potential to significantly improve survival rates while simultaneously reducing toxicity in cancer patients.